Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience.

Objective: To compare the characteristics, quality and treatment effects of randomised clinical trials (RCTs) by individual patient data (IPD) availability, in trials eligible for 18 IPD meta-analyses (MA).

Design: Trial characteristics, risk of bias (RoB) and hazard ratio (HR) for overall survival were extracted from IPD-MA publications and/or RCTs publications. Data for the RoB assessment were extracted for a subset of 73 RCTs.

Systematic reviews of therapeutic interventions frequently consider patient-important outcomes.

Objectives: To determine whether recently published and ongoing systematic reviews of therapeutic interventions assess patient-important outcomes.

Study Design And Setting: For this methodological review, we searched MEDLINE via PubMed for recently published systematic reviews and online registry of systematic reviews (PROSPERO) for ongoing systematic reviews. We selected systematic reviews with meta-analyses of randomized controlled trials.

Prognostic value of the infarct- and non-infarct like patterns and cardiovascular magnetic resonance parameters on long-term outcome of patients after acute myocarditis.

Background: Prognostic value of the infarct- and non-infarct like patterns and cardiac magnetic resonance (CMR) parameters on long-term outcome of patients after acute myocarditis is not well known.

Methods: Between 2006 and 2015, 112 consecutive patients with CMR-based diagnosis of acute myocarditis were identified in our institution. Of them, 88 were available for clinical follow-up and represented our studied population.

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.

Background: Sorafenib is the only systemic treatment that has shown a significant benefit in overall survival (OS) and in progression-free survival (PFS) in advanced hepatocellular carcinoma (HCC) patients. No standard of care currently exists for second-line treatment. The association of Gemcitabine-Oxaliplatine (GEMOX) has shown efficacy in the first-line setting.

Impact of extensive surgery in multidisciplinary approach of pterygopalatine/infratemporal fossa soft tissue sarcoma.

Background: To evaluate a strategy whereby extensive surgery ± external radiotherapy (RT) could improve local control in pterygopalatine/infratemporal fossa (PIF) sarcoma.

Procedure: Forty-one patients with a diagnosis of sarcoma involving the PIF and referred to our Institute from 1984 to 2009 were included in the analysis. Patients received multidrug chemotherapy and radiotherapy ± surgery, depending on the period of treatment.

[Cancer before age 40 in France].

Cancer is a rare pathology before the age of 40: a total of 14,000 new cases have been diagnosed in patients under age 40 in 2005, 1,700 under age 15 and 12,500 in the age-group of 15 to 39, this represents 4% of the cancers diagnosed in 2005. The number of deaths is small: in 2008, 2,235 patients died before age 40 in France, 246 under age 15 and 1,989 between age 15 and 39; this corresponds to 1% of the cancer deaths in 2008. The incidence increased between 1980 and 2005, both in the population aged 0 to 14 and in the population aged 15 to 39.